Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).

Bejarano I, Jiménez-Jorge S, Lobo-Acosta MÁ, Álvarez-López AI, Rosso-Fernández CM, López-Ruiz R, Eichau S, Ruiz-Peña JL, Géniz MÁ, Ampuero J, Ponce-España E, Merino-Bohorquez V, Cameán M, García-Sánchez MI, Izquierdo G, Guerrero JM, Romero-Gómez M, Lardone PJ, Carrillo-Vico A

Open source

DOI: 10.1007/s40263-025-01261-w
Published: 2026 Apr
Container: CNS drugs
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40263-025-01261-w,
  title = {Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).},
  author = {Bejarano I and Jiménez-Jorge S and Lobo-Acosta MÁ and Álvarez-López AI and Rosso-Fernández CM and López-Ruiz R and Eichau S and Ruiz-Peña JL and Géniz MÁ and Ampuero J and Ponce-España E and Merino-Bohorquez V and Cameán M and García-Sánchez MI and Izquierdo G and Guerrero JM and Romero-Gómez M and Lardone PJ and Carrillo-Vico A},
  year = {2026},
  journal = {CNS drugs},
  doi = {10.1007/s40263-025-01261-w},
  url = {https://doi.org/10.1007/s40263-025-01261-w}
}

RIS

TY  - JOUR
TI  - Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).
AU  - Bejarano I
AU  - Jiménez-Jorge S
AU  - Lobo-Acosta MÁ
AU  - Álvarez-López AI
AU  - Rosso-Fernández CM
AU  - López-Ruiz R
AU  - Eichau S
AU  - Ruiz-Peña JL
AU  - Géniz MÁ
AU  - Ampuero J
AU  - Ponce-España E
AU  - Merino-Bohorquez V
AU  - Cameán M
AU  - García-Sánchez MI
AU  - Izquierdo G
AU  - Guerrero JM
AU  - Romero-Gómez M
AU  - Lardone PJ
AU  - Carrillo-Vico A
PY  - 2026
JO  - CNS drugs
DO  - 10.1007/s40263-025-01261-w
UR  - https://doi.org/10.1007/s40263-025-01261-w
ER  -

APA

I, B., S, J., MÁ, L., AI, Á., CM, R., R, L., S, E., JL, R., MÁ, G., J, A., E, P., V, M., M, C., MI, G., G, I., JM, G., M, R., PJ, L., & A, C. (2026). Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1).. CNS drugs. https://doi.org/10.1007/s40263-025-01261-w

Source records

pubmed · retrieved 2026-09-25T10:56:21.216Z